Financial Reports and Presentations

2019

2024
2023
2022
2021
2020
2018
2017
2016
2015
2014
2012
2011
2010
2009
2008
2006
2005
All years

Annual reports

Interim reports
Annual reports
Presentations
Other
All types

	Report
September 5, 2019Annual Report 2018 / 2019

Share this page

Investor contact

[email protected]

+46 18-50 54 40

Subscribe to our news

Investors

About Us
Technology & Pipeline
Corporate Governance
Investors
Media
Contact

Vivesto is a Swedish development company that aims to offer new treatment options for hard-to-treat cancers where there are major medical needs and significant market potential. The project portfolio consists of Cantrixil and Docetaxel micellar, which are being developed for blood cancer and prostate cancer, respectively, and the veterinary oncology program Paccal Vet (paclitaxel micellar), which is being evaluated in a pilot clinical trial in dogs with splenic hemangiosarcoma.

The Share

Follow the share

Personal data
Cookies

OAS-MA-P-001-SEP2020

Box 3061
169 03 Solna, Sweden

Tel +46 18 50 54 40
Fax +46 18 51 08 73
info@vivesto.com